Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Activation in transformed cells of normal stem cells' self-renewal pathways might contribute to the survival life cycle of cancer stem cells and promote tumor progression. The BMI-1 oncogene-driven gene expression pathway is essential for the self-renewal of hematopoietic and neural stem cells. We applied a mouse/human comparative translational genomics approach to identify an 11-gene signature that consistently displays a stem cell-resembling expression profile in distant metastatic lesions as revealed by the analysis of metastases and primary tumors from a transgenic mouse model of prostate cancer and cancer patients. To further validate these results, we examined the prognostic power of the 11-gene signature in several independent therapy-outcome sets of clinical samples obtained from 1,153 cancer patients diagnosed with 11 different types of cancer, including 5 epithelial malignancies (prostate, breast, lung, ovarian, and bladder cancers) and 5 nonepithelial malignancies (lymphoma, mesothelioma, medulloblastoma, glioma, and acute myeloid leukemia). Kaplan-Meier analysis demonstrated that a stem cell-like expression profile of the 11-gene signature in primary tumors is a consistent powerful predictor of a short interval to disease recurrence, distant metastasis, and death after therapy in cancer patients diagnosed with 11 distinct types of cancer. These data suggest the presence of a conserved BMI-1-driven pathway, which is similarly engaged in both normal stem cells and a highly malignant subset of human cancers diagnosed in a wide range of organs and uniformly exhibiting a marked propensity toward metastatic dissemination as well as a high probability of unfavorable therapy outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated expression of this signature is associated with cancer development and chemotherapy resistance in different types of cancer, including hematological malignancies.11”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [11]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536 · cited 4×
“We therefore sought to investigate whether measurements of expression of the 11-gene MTTS/PNS signature would be informative in the prediction of the patients’ prognosis in a group of 97 young women diagnosed with sporadic lymph node– negative early-stage breast cancer who were analyzed in a recent expression profilin…”
BackgroundMethodInfluentialA Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Bhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191502998 · Cited by 2,576
Gene expression correlates of clinical prostate cancer behavior
Singh, D., Febbo, P. G., Ross, K., Jackson, D. G., Manola, J., Ladd, C., Tamayo, P., Renshaw, A. A., D'Amico, A. V., Richie, J. P., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00030-2 · Cited by 2,512
Systematic determination of genetic network architecture
Tavazoie, S., Hughes, J. D., Campbell, M. J., Cho, R. J., & Church, G. M. (1999) · Nature Genetics · doi:10.1038/10343 · Cited by 2,507 · cited 1×
“We calculated the significance of the overlap between the lists of stem cell–associated and prostate cancer–associated genes by using the hypergeometric distribution test (54).”
MethodA molecular signature of metastasis in primary solid tumors
Ramaswamy, S., Ross, K. N., Lander, E. S., & Golub, T. R. (2003) · Nature Genetics · doi:10.1038/ng1060 · Cited by 2,449
Shipp, M. A., Ross, K. N., Tamayo, P., Weng, A. P., Kutok, J. L., Aguiar, R. C. T., Gaasenbeek, M., Angelo, M., Reich, M., Pinkus, G. S., et al. (2002) · Nature Medicine · doi:10.1038/nm0102-68 · Cited by 2,428
Cited by
Items 201–300 of 914
de Jong, M. C., ten Hoeve, J. J., Grenman, R. A., Wessels, L. F. A., Kerkhoven, R. H., Riele, H. T., van den Brekel, M. W. M., Verheij, M., & Begg, A. C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0454 · Cited by 91
Biologic markers in endometrial cancer treatment
Engelsen, I. B., Akslen, L. A., & Salvesen, H. B. (2009) · Apmis · doi:10.1111/j.1600-0463.2009.02467.x · Cited by 102
“to represent a BMI-1-driven pathway (80, 81).”
Melo-Cardenas, J., Xu, Y., Wei, J., Tan, C., Kong, S., Gao, B., Montauti, E., Kirsammer, G., Licht, J. D., Yu, J., et al. (2018) · Blood · doi:10.1182/blood-2017-10-811760 · Cited by 84
Cancer stem cells niche: A target for novel cancer therapeutics
Yi, S., Hao, Y., Nan, K., & Fan, T. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.10.004 · Cited by 95
Cho, J.-H., Dimri, M., & Dimri, G. P. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.624361 · Cited by 89
“In addition to cellular senescence, BMI1 also promotes cancer stem cell phenotype and therapy resistance in cancer cells (11, 21).”
BackgroundBmi‐1 expression predicts prognosis for patients with gastric carcinoma
Liu, J., Song, L., Zhang, X., Guo, B., Feng, Y., Li, X., Liao, W., Zeng, M., & Huang, K. (2007) · Journal of Surgical Oncology · doi:10.1002/jso.20934 · Cited by 83
“[20–22], prostate cancer [23] and colorectal cancer [21].”
BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer
Crea, F., Serrat, M. A. D., Hurt, E. M., Thomas, S. B., Danesi, R., & Farrar, W. L. (2010) · International Journal of Cancer · doi:10.1002/ijc.25522 · Cited by 85
USP22 Acts as an Oncogene by the Activation of BMI-1-Mediated INK4a/ARF Pathway and Akt Pathway
Liu, Y., Jiang, S., Yang, Y., Xu, H., Liu, J.-L., & Wang, X. (2011) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-011-9287-0 · Cited by 87
“Recent studies [1], in the metastases and primary tumors from cancer patients and a transgenic mouse model of prostate cancer, employing a comparative and translational genomics approach led to the identification of an 11-gene Polycomb/cancer stem cell signature that could powerfully predict the therapeutic outcome of…”
BackgroundThe role of deubiquitinating enzymes in chromatin regulation
Atanassov, B. S., Koutelou, E., & Dent, S. Y. (2011) · FEBS Letters · doi:10.1016/j.febslet.2010.10.042 · Cited by 83
“Bmi1 and Ring1B are subunits of the mammalian PRC1 complex and the fact that Ring1B specifically represses p16Ink4a [69] may explain how Ring1B overexpression is linked to aggressive human tumors [68].”
BackgroundCho, J.-H., Dimri, M., & Dimri, G. P. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.422931 · Cited by 83
“The overexpression of BMI1 is also thought to promote stemness and therapy resistance in tumor cells (2, 17).”
BackgroundEnhancing Chemotherapy Response with Bmi-1 Silencing in Ovarian Cancer
Wang, E., Bhattacharyya, S., Szabolcs, A., Rodriguez-Aguayo, C., Jennings, N. B., Lopez-Berestein, G., Mukherjee, P., Sood, A. K., & Bhattacharya, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017918 · Cited by 82
“Also the increased expression of Bmi-1 was one of the key regulatory factors determining a cellular phenotype captured by the expression of a death-from-cancer signature in a broad spectrum of therapy-resistant clinically lethal malignancies [24].”
BackgroundTargeting Tumor Suppressor Networks for Cancer Therapeutics
Guo, X. E., Ngo, B., Modrek, A. S., & Lee, W. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106095151 · Cited by 106
Cancer stem cell‐like SP cells have a high adhesion ability to the peritoneum in gastric carcinoma
Nishii, T., Yashiro, M., Shinto, O., Sawada, T., Ohira, M., & Hirakawa, K. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01211.x · Cited by 80
Bub1 is required for maintaining cancer stem cells in breast cancer cell lines
Han, J. Y., Han, Y. K., Park, G., Kim, S., & Lee, C. G. (2015) · Scientific Reports · doi:10.1038/srep15993 · Cited by 87
Genome-wide analysis of microRNA and mRNA expression signatures in cancer
Li, M., Fu, S., & Xiao, H. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.67 · Cited by 93
Gieni, R. S., Ismail, I. H., Campbell, S., & Hendzel, M. J. (2011) · Cell Cycle · doi:10.4161/cc.10.6.14907 · Cited by 71
USP22 controls necroptosis by regulating receptor-interacting protein kinase 3 ubiquitination
Roedig, J., Kowald, L., Juretschke, T., Karlowitz, R., Abhari, B. A., Roedig, H., Fulda, S., Beli, P., & van Wijk, S. J. L. (2020) · EMBO Reports · doi:10.15252/embr.202050163 · Cited by 79
“…USP22 expression is closely associated with neurodegenerative diseases, carcinogenesis, and poor patient survival in a wide range of tumor types (Glinsky et al , 2005; Liu et al , 2010; Liu et al , 2011; Yang et al , 2011; Zhang et al , 2011; Piao et al , 2012; Li et al , 2012b; Wang et al ,…”
Yeon, S. Y., Jo, Y. S., Choi, E. J., Kim, M. S., Yoo, N. J., & Lee, S. H. (2017) · Pathology & Oncology Research · doi:10.1007/s12253-017-0287-2 · Cited by 76
Gieni, R. S., & Hendzel, M. J. (2009) · Biochemistry and Cell Biology · doi:10.1139/o09-057 · Cited by 82
“Numerous studies have found that tumors with stem cell like gene expression profiles, characterized by deregulation of the polycomb system, are aggressive and are more likely to survive the existing cancer therapies (Glinsky et al. 2005, 2006, 2007, 2008).”
BackgroundGoldstein, A. S., Stoyanova, T. I., & Witte, O. N. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.06.009 · Cited by 81
“Other genes and pathways that regulate stem cell selfrenewal and similar developmental processes, such as the Wnt [106–110] and Notch pathways [111–117], c-Myc [118,119], Bcl-2 [120,121] and Bmi1 [122–124], have altered expression in prostate cancer and may be involved in cancer cell survival and self-renewal.”
BackgroundRoca, H., Craig, M. J., Chi, Y., Varsos, Z. S., Czarnieski, P., Alva, A. S., Hernandez, J. R., Fuller, D. E. H., Daignault, S. D., Healy, P. N., et al. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24025 · Cited by 76
“JOURNAL OF CELLULAR BIOCHEMISTRY IL-4 INDUCES PROSTATE CANCER PROLIFERATION 1575 et al., 2002; Glinsky et al., 2005].”
BackgroundLiao, Y.-P., Chen, L.-Y., Huang, R., Su, P., Chan, M. W. Y., Chang, C., Yu, M., Wang, P., Yen, M.-S., Nephew, K. P., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt583 · Cited by 71
HNF1A is a novel oncogene that regulates human pancreatic cancer stem cell properties
Abel, E. V., Goto, M., Magnuson, B., Abraham, S. T., Ramanathan, N., Hotaling, E., Alaniz, A. A., Kumar‐Sinha, C., Dziubinski, M. L., Urs, S., et al. (2018) · eLife · doi:10.7554/elife.33947 · Cited by 83
The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors
Bommi, P. V., Dimri, M., Sahasrabuddhe, A. A., Khandekar, J. D., & Dimri, G. P. (2010) · Cell Cycle · doi:10.4161/cc.9.13.12147 · Cited by 76
“BMI1 has been proposed to promote stem-ness in tumors and its overexpresion has been correlated with a death from cancer signature in cancer patients.(8,12) Recently a micro RNA cluster miR-200c was shown to regulate BMI1 expression in mammary epithelial stem cells, and its downregulation was shown to result in BMI1 u…”
BackgroundOverexpression of BMI-1 Promotes Cell Growth and Resistance to Cisplatin Treatment in Osteosarcoma
Wu, Z., Min, L., Chen, D., Hao, D., Duan, Y., Qiu, G., & Wang, Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014648 · Cited by 74
“cancers including nasopharyngeal was associated with poor patient outcome [15,16].”
Breast cancer prognostication and prediction: are we making progress?
Lønning, P. E. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm260 · Cited by 72
Expression patterns of USP22 and potential targets BMI-1, PTEN, p-AKT in non-small-cell lung cancer
Hu, J., Liu, Y., Piao, S., Yang, D., Yang, Y., & Cai, L. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.05.112 · Cited by 74
Lv, L., Xiao, X., Gu, Z., Zeng, F., Huang, L., & Jiang, G. (2010) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-010-0585-4 · Cited by 72
“More importantly, recent studies have suggested that USP22 may be a valuable biomarker for predicting the recurrence and metastasis of malignance and its resistance to chemotherapy [8, 9].”
BackgroundRøe, O. D., Anderssen, E., Sandeck, H., Christensen, T., Larsson, E., & Lundgren, S. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.03.016 · Cited by 78
Role of Hedgehog Signaling in Malignant Pleural Mesothelioma
Shi, Y., Moura, U., Opitz, I., Soltermann, A., Rehrauer, H., Thies, S., Weder, W., Stahel, R. A., & Felley‐Bosco, E. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0599 · Cited by 78
“Activated stem cell signaling has already been suggested in MPM with the presence of an 11-gene signature, correlating with a stem-cell-like expression profile, which is associated with a poor prognosis in patients with MPM (3).”
BackgroundEfficient Immortalization of Primary Nasopharyngeal Epithelial Cells for EBV Infection Study
Yip, Y. L., Pang, P. S., Deng, W., Tsang, C. M., Zeng, M., Hau, P. M., Man, C., Jin, Y., Yuen, A. P. W., & Tsao, S. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078395 · Cited by 74
“The primers sequences for the genes in Bmi-1 driven pathways and for the EBV-encoded transcripts have been published [16,17].”
Rajabi, H. N., Hiraki, M., & Kufe, D. W. (2018) · Oncogene · doi:10.1038/s41388-017-0096-9 · Cited by 72
Liu, Y. L., Yang, Y. M., Xu, H., & Dong, X. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06352.x · Cited by 72
Prostate cancer stem cells and their potential roles in metastasis
Li, H., & Tang, D. G. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.21806 · Cited by 72
“Second, gene expression profile studies on PCa identified an 11-gene signature that included ‘‘stemness’’ genes such as BMI-1 in highly metastatic PCa and also predicted poor outcomes in PCa patients [51,52].”
BackgroundVormittag, L., Thurnher, D., Geleff, S., Pammer, J., Heiduschka, G., Brunner, M., Grasl, M. C., & Erović, B. M. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.10.040 · Cited by 69
Yang, D., Cui, B., Sun, L., Zheng, H., Huang, Q., Tong, J., & Zhang, Q.-F. (2011) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-011-9229-x · Cited by 73
“In fact, increased expression of the BMI-1 oncogene is one of the key regulatory factors determining a cellular phenotype captured by the expression of deathfrom-cancer signature in a broad spectrum of therapyresistant clinically lethal malignancies [1, 2, 5].”
BackgroundRole of polycomb proteins Ring1A and Ring1Bin the epigenetic regulation of gene expression
Vidal, M. (2009) · The International Journal of Developmental Biology · doi:10.1387/ijdb.082690mv · Cited by 79
Lancashire, L., Powe, D. G., Reis-Filho, J. S., Rakha, E. A., Lemetre, C., Weigelt, B., Abdel-Fatah, T. M. A., Green, A. R., Mukta, R., Blamey, R. W., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0378-1 · Cited by 85
“Similar findings have been reported [48] where HEC was identified as part of an 11 gene signature predictive of disease recurrence and distant metastasis in prostate and breast cancer.”
ResultAlajez, N. M., Shi, W., Hui, A. B., Yue, S., Ng, R., Lo, K. W., Bastianutto, C., O’Sullivan, B., Gullane, P., & Liu, F. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.85 · Cited by 70
Predicting Recurrence After Radiotherapy in Head and Neck Cancer
Begg, A. C. (2012) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2011.12.002 · Cited by 77
The Polycomb Group Protein Bmi-1 Is Essential for the Growth of Multiple Myeloma Cells
Jagani, Z., Wiederschain, D., Loo, A. T., He, D., Mosher, R. E., Fordjour, P., Monahan, J. E., Morrissey, M., Yao, Y.-M., Lengauer, C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4229 · Cited by 81
“ture is a predictor of metastasis and poor survival (15, 16).”
BackgroundXian, W., Schwertfeger, K. L., & Rosen, J. M. (2007) · Molecular Endocrinology · doi:10.1210/me.2006-0518 · Cited by 70
“The finding that FGFR2 belongs to three genes that are down-regulated in an 11-gene signature associated with poor prognosis of cancer patients with multiple types of cancer including breast cancer (48) suggests that FGFR2 may function as tumor suppressor.”
BackgroundHippo/YAP pathway for targeted therapy
Felley‐Bosco, E., & Stahel, R. A. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.02.03 · Cited by 81
“Activated stem cell signalling has already been suggested in MPM by the presence of an 11-gene signature, correlated with a stem-cell-like expression profile, which is associated with a poor prognosis in patients with MPM (46).”
BackgroundMcCann, J. J., Vasilevskaya, I. A., Neupane, N. P., Shafi, A. A., McNair, C. M., Dylgjeri, E., Mandigo, A. C., Schiewer, M. J., Schrecengost, R. S., Gallagher, P., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1033 · Cited by 72
Pils, D., Hager, G., Castillo‐Tong, D. C., Aust, S., Heinze, G., Kohl, M., Schuster, E., Wolf, A. M., Sehouli, J., Braicu, E. I., et al. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02306.x · Cited by 69
Gene Expression Profiling to Predict Outcome After Chemoradiation in Head and Neck Cancer
Pramana, J., van den Brekel, M. W. M., van Velthuysen, M. F., Wessels, L. F. A., Nuyten, D. S. A., Hofland, I., Atsma, D., Pimentel, N., Hoebers, F. J. P., Rasch, C. R. N., et al. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.08.032 · Cited by 76
Tateishi, K., Ohta, M., Kanai, F., Guleng, B., Tanaka, Y., Asaoka, Y., Tada, M., Seto, M., Jazag, A., Lianjie, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0449 · Cited by 69
Cancer Stem Cell Epigenetics And Chemoresistance
Crea, F., Danesi, R., & Farrar, W. L. (2009) · Epigenomics · doi:10.2217/epi.09.4 · Cited by 74
Roukos, D. H. (2007) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.8.1.29 · Cited by 71
Ahmed, N., Kadife, E., Raza, A., Short, M. K., Jubinsky, P. T., & Kannourakis, G. (2020) · Cells · doi:10.3390/cells9030719 · Cited by 72
Lymphoma stem cells: enough evidence to support their existence?
Martinez-Climent, J. A., Fontán, L., Gascoyne, R. D., Siebert, R., & Prósper, F. (2010) · Haematologica · doi:10.3324/haematol.2009.013318 · Cited by 85
“resistant to radiotherapy and chemotherapy-induced apoptosis, which allows these cells to survive and generate tumor relapse.(14,15) A prototypical example of a stem cell disorder is chronic myeloid leukemia (CML), where the tyrosine kinase inhibitor imatinib has replaced IFNa as the standard therapy.”
BackgroundGenomics and proteomics: Emerging technologies in clinical cancer research
Chung, C. H., Levy, S., Chaurand, P., & Carbone, D. P. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.06.005 · Cited by 74
“[47] Glinsky GV, Berezovska O, Glinskii AB.”
BackgroundSynthesis and Biological Evaluation of a Series of Novel Inhibitor of Nek2/Hec1 Analogues
Qiu, X., Li, G., Wu, G., Zhu, J., Zhou, L., Chen, P., Chamberlin, A. R., & Lee, W. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8015969 · Cited by 66
Balasubramanian, S., Chew, Y. C., & Eckert, R. L. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.072363 · Cited by 66
“Elevated Bmi-1 expression is observed in prostate, lung, breast, ovarian, and skin cancer (Glinsky et al., 2005; Lee et al., 2008), and Ezh2 is amplified and overexpressed in prostate, pancreas, breast, and ovarian cancer (Liu et al., 1992; Kleer et al., 2003).”
BackgroundStem cell protein BMI‐1 is an independent marker for poor prognosis in oligodendroglial tumours
Häyry, V., Tynninen, O., Haapasalo, H., Wölfer, J., Paulus, W., Hasselblatt, M., Sariola, H. V., Paetau, A. E., Sarna, S. J., Niemela, M. R., et al. (2008) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2008.00949.x · Cited by 65
Glinskii, A. B., Ma, J., Ma, S., Grant, D., Lim, C.-U., Sell, S., & Glinsky, G. (2009) · Cell Cycle · doi:10.4161/cc.8.23.10113 · Cited by 65
Self-citationTyagi, S., & Herr, W. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.258 · Cited by 77
“E2F1 mediates DNA damage and apoptosis through HCF-1 and the MLL family of histone methyltransferases”
BackgroundRole of Sox2 and Oct4 in predicting survival of hepatocellular carcinoma patients after hepatectomy
Huang, P., Qiu, J., Li, B., Hong, J., Lu, C., Wang, L., Wang, J., Hu, Y., Jia, W., & Yuan, Y. (2011) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2011.02.012 · Cited by 65
Thomas, R. S., Pluta, L., Yang, L., & Halsey, T. A. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfm023 · Cited by 65
“A previous study was able to predict chemically induced rat liver tumors following a 24-h exposure with 84% accuracy using only six genes (Nie et al., 2006), and an 11 gene signature was able to predict recurrence, metastasis, and death in a variety of cancers (Glinsky et al., 2005).”
BackgroundResultInfluentialGene expression profiling in breast cancer
Morris, S. R., & Carey, L. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3282f0ada3 · Cited by 67
Histone H2B ubiquitination: the cancer connection
Espinosa, J. M. (2008) · Genes & Development · doi:10.1101/gad.1732108 · Cited by 72
“Recent advances in transcriptional profiling of tumor cells generated an 11- gene signature associated with poor prognosis (i.e., short interval to disease recurrence, distant metastasis and death after therapy) (Glinsky et al. 2005).”
BackgroundDeubiquitinating enzymes regulate Hes1 stability and neuronal differentiation
Kobayashi, T., Iwamoto, Y., Takashima, K., Isomura, A., Kosodo, Y., Kawakami, K., Nishioka, T., Kaibuchi, K., & Kageyama, R. (2015) · FEBS Journal · doi:10.1111/febs.13290 · Cited by 68
Discovery of prostate cancer biomarkers by microarray gene expression profiling
Sørensen, K. D., & Orntoft, T. F. (2009) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.09.74 · Cited by 65
USP22 exerts tumor-suppressive functions in colorectal cancer by decreasing mTOR activity
Kosinsky, R. L., Zerche, M., Saul, D., Wang, X., Wohn, L., Wegwitz, F., Begus‐Nahrmann, Y., & Johnsen, S. A. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0420-8 · Cited by 68
Mimeault, M., & Batra, S. K. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.08.001 · Cited by 68
“…cancer progression and metastases at surrounding and distant tissues and associated with a poor prognosis of cancer patients (Bismar et al., 2006; Glinsky et al., 2005; Manjili et al., 2012; Marchini et al., 2010; Markert et al., 2011; Perez-Villamil et al., 2012; Sergeant et al., 2012; Van…”
BackgroundYoo, Y. A., Roh, M., Naseem, A. F., Lysy, B., Desouki, M. M., Unno, K., & Abdulkadir, S. A. (2016) · Nature Communications · doi:10.1038/ncomms12943 · Cited by 70
Invincible, but Not Invisible: Imaging Approaches Toward In Vivo Detection of Cancer Stem Cells
Hart, L. S., & El‐Deiry, W. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.9573 · Cited by 61
Armour, S. M., Bennett, E. J., Braun, C. R., Zhang, X.-Y., McMahon, S. B., Gygi, S. P., Harper, J. W., & Sinclair, D. A. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00971-12 · Cited by 62
“For instance, USP22 has been shown to be part of an 11-gene death-from-cancer signature that is predictive of treatment failure (48, 49), and its increased expression is associated with a poor prognosis in a variety of cancers (50, 51).”
BackgroundCurrent Status and Issues in Cancer Stem Cell Study
Yang, Y., & Chang, J. (2008) · Cancer Investigation · doi:10.1080/07357900801901856 · Cited by 69
“Furthermore, this metastasis/stem cell signature could be used to predict the risk of metastatic recurrence and poor clinical outcomes using samples from 1, 153 cancer patients with 11 different types of cancer (62).”
Medulloblastoma stem cells: where development and cancer cross pathways
Manoranjan, B., Venugopal, C., McFarlane, N., Doble, B. W., Dunn, S. E., Scheinemann, K., & Singh, S. K. (2012) · Pediatric Research · doi:10.1038/pr.2011.62 · Cited by 72
“The Bmi1 signaling pathway is also consistently dysregulated or overexpressed in several emerging CSC populations, most recently being cited as a marker of recurrence, poor treatment response, metastatic potential, and death in many cancer models, including MB (59,60).”
BackgroundDzobo, K., & Sinkala, M. (2021) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2021.0025 · Cited by 69
“While investigations are continuing on the role of CSCs, recent reports demonstrate that they are linked to poor prognosis in several cancers (Dzobo et al., 2016, 2020a, 2020b; Glinsky et al., 2005).”
A deubiquitination module essential for T reg fitness in the tumor microenvironment
Montauti, E. I., Weinberg, S. E., Chu, P., Chaudhuri, S. M., Mani, N. L., Iyer, R., Zhou, Y., Zhang, Y., Liu, C., Xin, C., et al. (2022) · Science Advances · doi:10.1126/sciadv.abo4116 · Cited by 71
Loss of BMI-1 expression is associated with clinical progress of malignant melanoma
Bachmann, I. M., Puntervoll, H. E., Otte, A. P., & Akslen, L. A. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.17 · Cited by 60
Gene expression profiling of Non-small cell lung cancer
Singhal, S. K., Miller, D., Ramalingam, S. S., & Sun, S. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.03.007 · Cited by 62
“Other examples of genetic alterations in NSCLC that have been discovered or screen in a large number of tumors in a very short time using high-throughput gene expression array technology include thyroid transcription factor-1 [18], BMI-1 [19], PEX1 [20], MKK7 [20], HDAC 3 [20], insulin-like growth factor-binding prote…”
BackgroundRole of Host Cell Factor-1 in cell cycle regulation.
Zargar, Z. U., & Tyagi, S. (2012) · Transcription · doi:10.4161/trns.20711 · Cited by 68
“1-4 Importantly, the discovery that gene-encoding HCF-1 is over-expressed in tumors, and this over-expression is a marker that predicts poor prognosis in cancer treatment proves that the functions of HCF-1 are more complex than previously appreciated.(5) Role of host cell factor-1 in cell cycle regulation”
BackgroundThe mammary cellular hierarchy and breast cancer
Oakes, S. R., Gallego‐Ortega, D., & Ormandy, C. J. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1674-4 · Cited by 73
Wang, A., Ning, Z., Lu, C., Gao, W., Liang, J., Yan, Q., Tan, G., & Liu, J. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00274 · Cited by 69
“USP22, a novel deubiquitinating enzyme and a member comprising the 11 gene Polycomb/cancer stem cell signature, possesses the functions such as transcription activation, epigenetic regulation and cancer progression (Glinsky et al., 2005; Glinsky, 2006, 2008).”
BackgroundWang, Z., Zhu, L., Guo, T., Wang, Y., & Yang, J. (2015) · Human Pathology · doi:10.1016/j.humpath.2015.04.001 · Cited by 60
A novel role for Plk4 in regulating cell spreading and motility
Rosario, C. O., Kazazian, K., Zih, F. S. W., Brashavitskaya, O., Haffani, Y. Z., Xu, R., George, A., Dennis, J. W., & Swallow, C. J. (2014) · Oncogene · doi:10.1038/onc.2014.275 · Cited by 58
Bhaijee, F., Pepper, D. J., Pitman, K. T., & Bell, D. (2011) · Head & Neck · doi:10.1002/hed.21801 · Cited by 72
“BMI-1 is a stem-cell–related gene,(56) which participates in the self-renewal of hematopoietic(57) and neuronal(58) stem cells, and has been implicated in the tumorigenesis of various malignancies, including leukemias, lymphomas, lung cancer, and breast cancer.(59) Based on microarray analysis, Glinsky et al(59) sugge…”
BackgroundWang, H., Chen, N. G., Minev, B., & Szalay, A. A. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-167 · Cited by 64
“A link between cancer stem cells and secondary tumor metastases was first suggested after the identification of “stemness” and an 11-gene signature therapy resistant profile of metastatic and primary tumors in prostate cancer of a transgenic mouse model, as well as in cancer patients [47].”
BackgroundBmi1 promotes prostate tumorigenesis via inhibiting p16INK4A and p14ARF expression
Fan, C., He, L., Kapoor, A., Gillis, A., Rybak, A. P., Cutz, J., & Tang, D. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.08.009 · Cited by 67
Jeusset, L. M., & McManus, K. J. (2017) · Cancers · doi:10.3390/cancers9120167 · Cited by 66
“This gene signature identifies a small subset of patients with early-stage prostate, breast or lung carcinoma who are more likely to face shorter intervals to recurrence, metastatic dissemination and death after therapy [41,42].”
BackgroundMoharita, A. L., Taborga, M., Corcoran, K. E., Bryan, M., Patel, P. S., & Rameshwar, P. (2006) · Blood · doi:10.1182/blood-2006-01-017459 · Cited by 61
Clonal Persistence and Evolution During a Decade of Recurrent Melanoma
Wang, E., Voiculescu, S. E., Poole, I. C. L., El‐Gamil, M., Li, X., Sabatino, M., Robbins, P. F., Nickoloff, B. J., & Marincola, F. M. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700193 · Cited by 58
“It remains, however, unclear whether disease recurrences originate from genetically unrelated clones differently affected by the previous treatment, or a single cancer stem clone that survives treatment and perpetuates the disease (Reya et al., 2001; Glinsky et al., 2005).”
BackgroundSchmid (2010) · International Journal of Oncology · doi:10.3892/ijo_00000692 · Cited by 59
Proliferation State and Polo-Like Kinase1 Dependence of Tumorigenic Colon Cancer Cells
Francescangeli, F., Patrizii, M., Signore, M., Federici, G., Franco, S. D., Pagliuca, A., Baiocchi, M., Biffoni, M., Ricci‐Vitiani, L., Todaro, M., et al. (2012) · Stem Cells · doi:10.1002/stem.1163 · Cited by 64
Gomez, L. A., Pozas, A. D. L., Reiner, T., Burnstein, K. L., & Perez‐Stable, C. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0727 · Cited by 64
A portrayal of E3 ubiquitin ligases and deubiquitylases in cancer
Satija, Y. K., Bhardwaj, A., & Das, S. (2013) · International Journal of Cancer · doi:10.1002/ijc.28129 · Cited by 72
Jhavar, S. G., Brewer, D. S., Edwards, S. E., Kote‐Jarai, Z., Attard, G., Clark, J., Flohr, P., Christmas, T. J., Thompson, A. C., Parker, M. D., et al. (2008) · British Journal of Urology · doi:10.1111/j.1464-410x.2008.08200.x · Cited by 61
de Haas, T. G., Hasselt, N. E., Troost, D., Caron, H. N., Popović, M., Zaletel, L. Z., Grajkowska, W., Perek‐Polnik, M., Osterheld, M., Ellison, D. W., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4159 · Cited by 64
Zhang, K., Yang, L., Wang, J., Sun, T., Guo, Y., Nelson, R. A., Tong, T. R. S.-W., Pangeni, R. P., Salgia, R., & Raz, D. J. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0480-x · Cited by 59
“Interestingly, an earlier study identified that USP22 is one of an 11-gene transcriptional signature which was associated with aggressive growth, metastasis, and therapy resistance in a number of human cancers including lung cancer [8].”
A Perspective on DNA Microarrays in Pathology Research and Practice
Pollack, J. R. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.070342 · Cited by 62
Histones and Their Modifications in Ovarian Cancer – Drivers of Disease and Therapeutic Targets
Marsh, D. J., Shah, J. S., & Cole, A. J. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00144 · Cited by 65
“Further, there is considerable interest in the H2Bub1-targeting DUB USP22 given its membership of an 11-gene panel termed the “Death-from-Cancer” signature that predicts rapid disease recurrence, distal metastasis, and poor response to therapy (142).”
BackgroundUbiquitin-specific peptidase 22 in cancer
Feng, T., Ling, S., Xu, C., Ying, L., Su, D., & Xu, X. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.05.004 · Cited by 63
Regulation of cancer stem cell properties by CD9 in human B-acute lymphoblastic leukemia
Yamazaki, H., Xu, C. W., Naito, M., Nishida, H., Okamoto, T., Ghani, F. I., Iwata, S., Inukai, T., Sugita, K., & Morimoto, C. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.04.098 · Cited by 61
Hu, C.-M., Zhu, J., Guo, X. E., Chen, W., Qiu, X.-L., Ngo, B., Chien, R., Wang, Y., Tsai, C. Y., Wu, G., et al. (2014) · Oncogene · doi:10.1038/onc.2014.67 · Cited by 57
Altered gene expression in breast cancer liver metastases
Erin, N., Wang, N., Xin, P., Bui, V., Weisz, J., Barkan, G. A., Zhao, W., Shearer, D. A., & Clawson, G. A. (2009) · International Journal of Cancer · doi:10.1002/ijc.24131 · Cited by 64
“In the third study using a mouse/human comparative translational genomic approach, Glinsky et al.63 identified an 11-gene signature displaying a stem cell expression profile in metastatic lesions.”
BackgroundTranscriptional Profiling of Mammary Gland Side Population Cells
Behbod, F., Xian, W., Shaw, C. A., Hilsenbeck, S. G., Tsimelzon, A. I., & Rosen, J. M. (2005) · Stem Cells · doi:10.1634/stemcells.2005-0375 · Cited by 61
“therapy failure and poor prognosis in patients with solid as well as hematopoietic cancers [38].”
BackgroundSethi, G., Pathak, H. B., Zhang, H., Zhou, Y., Einarson, M. B., Vathipadiekal, V., Gunewardena, S., Birrer, M. J., & Godwin, A. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047086 · Cited by 64
“[46] Overexpression of NDC80 and NUF2 has been related to poor clinical prognosis in patients with breast cancers and non-small cell lung cancers [43,47].”
Background
Metadata
- Authors
- Glinsky, G. V., Berezovska, O., & Glinskii, A. B.
- Affiliations
- Sidney Kimmel Cancer Center (US)
- Corresponding author
- Glinsky, Gennadi V.
- ORCID
- Glinsky, Gennadi V.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-06-01
- Volume
- 115
- Issue
- 6
- Pages
- 1503-1521
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1136989
- OpenAlex
- W2166666333
- Cited by
- 916
- References
- 68
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 22 · 2023: 30 · 2022: 25 · 2021: 29 · 2020: 25 · 2019: 27 · 2018: 38 · 2017: 35 · 2016: 30 · 2015: 50 · 2014: 57 · 2013: 51 · 2012: 60
- FWCI
- 34.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Memorial Sloan-Kettering Cancer Center
- National Institutes of Health
- National Cancer Institute (5R01CA89827, R01CA089827)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- cancer stem cells, BMI1, stem cell self-renewal, gene expression signatures, metastasis, treatment failure, prognosis, distant metastasis, recurrence, epithelial malignancies, hematologic malignancies, multi-cancer analysis
- MeSH terms
- Animals, Female, Humans, Male, Mice, Transgenic, Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasms, Nuclear Proteins, Prognosis, Proto-Oncogene Proteins, Repressor Proteins, Biomarkers, Tumor, Neoplastic Stem Cells, Gene Expression Regulation, Neoplastic, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Mice, Polycomb Repressive Complex 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.